No Impact of Prophylactic Corticosteroid Use in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma

被引：0
|
作者：
Melody, Megan [1 ,2 ]
Franco, Stephanie [3 ]
Odetola, Oluwatobi [1 ,2 ]
Lin, Adam [1 ,2 ]
Moreira, Jonathan [1 ,2 ]
Carson, Kenneth [1 ,2 ]
Ma, Shuo [1 ,2 ]
Winter, Jane N. [1 ,2 ]
Gordon, Leo [1 ,2 ]
Karmali, Reem [1 ,2 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CT; LBCL; CAR T-cell therapy; CRS; ICANS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT-630
引用
收藏
页码：S611 / S612
页数：2
相关论文
共 50 条
  • [21] The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
    Kitsada Wudhikarn
    Radhika Bansal
    Arushi Khurana
    Matthew A. Hathcock
    N. Nora Bennani
    Jonas Paludo
    Jose C. Villasboas
    Yucai Wang
    Patrick B. Johnston
    Stephen M. Ansell
    Yi Lin
    Blood Cancer Journal, 11
  • [22] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
  • [23] Cautionary Tale of Unopposed Prophylactic IL6 Receptor Blockade in Axicabtagene ciloleucel for Large B-Cell Lymphoma
    Valtis, Yannis K.
    Park, Jae H.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (11): : 1042 - 1044
  • [24] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
    Khurana, Arushi
    Bailey, Megumi
    Iqbal, Madiha
    Bansal, Radhika
    Lee, Catherine J.
    Hunter, Bradley
    Lunning, Matthew A.
    Jaglowski, Samantha
    Jain, Michael D.
    Dahiya, Saurabh
    Bachanova, Veronika
    Farooq, Umar
    Ahmed, Sairah
    Hill, Brian T.
    Munoz, Javier L.
    Patel, Krish
    Oluwole, Olalekan O.
    Lin, Yi
    BLOOD, 2022, 140 : 4657 - 4660
  • [25] EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma
    Papadouli, Irene
    Mueller-Berghaus, Jan
    Beuneu, Claire
    Ali, Sahra
    Hofner, Benjamin
    Petavy, Frank
    Tzogani, Kyriaki
    Miermont, Anne
    Norga, Koenraad
    Kholmanskikh, Olga
    Leest, Tim
    Schuessler-Lenz, Martina
    Salmonson, Tomas
    Gisselbrecht, Christian
    Garcia, Jordi Llinares
    Pignatti, Francesco
    ONCOLOGIST, 2020, 25 (10): : 894 - 902
  • [26] Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
    Locke, Frederick L.
    Neelapu, Sattva S.
    Bartlett, Nancy L.
    Lekakis, Lazaros J.
    Jacobson, Caron A.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Siddiqi, Tanya
    Lin, Yi
    Timmerman, John M.
    Kersten, Marie Jose
    Zheng, Yan
    Zhang, Teresa
    Nater, Jenny
    Shen, Rhine
    Miao, Harry
    Kim, Jenny J.
    Miklos, David B.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (11): : 1065 - 1079
  • [27] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
    Koji Kato
    Shinichi Makita
    Hideki Goto
    Junya Kanda
    Nobuharu Fujii
    Kazuyuki Shimada
    Koichi Akashi
    Koji Izutsu
    Takanori Teshima
    Natsuko Fukuda
    Tokuhito Sumitani
    Hiroyuki Sumi
    Shinji Shimizu
    Yasuyuki Kakurai
    Kenji Yoshikawa
    Kensei Tobinai
    Noriko Usui
    Kiyohiko Hatake
    International Journal of Clinical Oncology, 2022, 27 : 213 - 223
  • [28] Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
    Strati, Paolo
    Furqan, Fateeha
    Westin, Jason
    Fayad, Luis
    Ahmed, Sairah
    Lee, Hun Ju
    Iyer, Swaminathan Padmanabhan
    Nair, Ranjit
    Nastoupil, Loretta J.
    Parmar, Simrit
    Rodriguez, Maria Alma
    Samaniego, Felipe
    Steiner, Raphael
    Wang, Michael
    Pinnix, Chelsea Camille
    Flowers, Christopher
    Horowitz, Sandra B.
    Classen, Catherine
    Mistry, Haleigh
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
    Bouchkouj, Najat
    Kasamon, Yvette L.
    de Claro, R. Angelo
    George, Bindu
    Lin, Xue
    Lee, Shiowjen
    Blumenthal, Gideon M.
    Bryan, Wilson
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (06) : 1702 - 1708
  • [30] Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
    Pinnix, Chelsea C.
    Gunther, Jillian R.
    Dabaja, Bouthaina S.
    Strati, Paolo
    Fang, Penny
    Hawkins, Misha C.
    Adkins, Sherry
    Westin, Jason
    Ahmed, Sairah
    Fayad, Luis
    Lee, Hun Ju
    Nair, Ranjit
    Steiner, Raphael E.
    Iyer, Swaminathan P.
    Rodriguez, M. Alma
    Wang, Michael
    Flowers, Christopher
    Neelapu, Sattva S.
    Nastoupil, Loretta J.
    BLOOD ADVANCES, 2020, 4 (13) : 2871 - 2883
12345